Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 4, 2012, Pages 478-488

  Brandt, Oliver ^a   Mildner, Michael ^a   Egger, Alexander E ^b   Groessl, Michael ^b   Rix, Uwe ^c   Posch, Martin ^d   Keppler, Bernhard K ^b   Strupp, Christian ^e   Mueller, Beat ^e   Stingl, Georg ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e Spirig Pharma Ltd   (Switzerland)

Author keywords

Antimicrobial potency; Internal organ deposition; Percutaneous absorption; Silver ions

Indexed keywords

ANTI-MICROBIAL ACTIVITY; ANTIBACTERIAL AGENT; ANTIMICROBIAL POTENCY; BACTERIAL STRAINS; INTERNAL ORGANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MURINE MODEL; NANOSCALE SILVER; PERCUTANEOUS ABSORPTION; SIDE EFFECT; SILVER DEPOSITION; SILVER IONS; SILVER SULFADIAZINES; SKIN INFECTION; TOPICAL APPLICATION;

BACTERIA; METAL IONS; YEAST;

SILVER;

SILVER NANOPARTICLE; SULFADIAZINE SILVER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DERMATOPHYTE; DRUG ABSORPTION; DRUG FORMULATION; DRUG POTENCY; FEMALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; SKIN ABSORPTION; YEAST;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; ARTHRODERMATACEAE; BURNS; DERMATOMYCOSES; FEMALE; METAL NANOPARTICLES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, MUTANT STRAINS; SILVER; SILVER SULFADIAZINE; STAPHYLOCOCCAL SKIN INFECTIONS;

BACTERIA (MICROORGANISMS); FUNGI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MURINAE;

EID: 84860229124     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.07.005     Document Type: Article

References (54)

1. Lansdown A.B. Critical observations on the neurotoxicity of silver. Crit Rev Toxicol 2007, 37:237-250.
2. Klasen H.J. Historical review of the use of silver in the treatment of burns. I. Early uses. Burns 2000, 26:117-130.
3. Jappe U., Heuck D., Strommenger B., Wendt C., Werner G., Altmann D., et al. Staphylococcus aureus in dermatology outpatients with special emphasis on community-associated methicillin-resistant strains. J Invest Dermatol 2008, 128:2655-2664.
4. Lansdown A.B. Silver. I: Its antibacterial properties and mechanism of action. J Wound Care 2002, 11:125-130.
5. White R., Cutting K. Exploring the effects of silver in wound management-what is optimal. Wounds 2006, 18:307-314.
6. Fox C.L. Silver sulfadiazine-a new topical therapy for Pseudomonas in burns. Therapy of Pseudomonas infection in burns. Arch Surg 1968, 96:184-188.
7. Speck W.T., Rosenkranz H.S. Activity of silver sulphadiazine against dermatophytes [letter]. Lancet 1974, 2:895-896.
8. Wlodkowski T.J., Rosenkranz H.S. Antifungal activity of silver sulphadiazine. Lancet 1973, 2:739-740.
9. Betbeze C.M., Wu C.C., Krohne S.G., Stiles J. In vitro fungistatic and fungicidal activities of silver sulfadiazine and natamycin on pathogenic fungi isolated from horses with keratomycosis. Am J Vet Res 2006, 67:1788-1793.
10. Tsipouras N., Rix C.J., Brady P.H. Solubility of silver sulfadiazine in physiological media and relevance to treatment of thermal burns with silver sulfadiazine cream. Clin Chem 1995, 41:87-91.
11. Wan A.T., Conyers R.A., Coombs C.J., Masterton J.P. Determination of silver in blood, urine, and tissues of volunteers and burn patients. Clin Chem 1991, 37:1683-1687.
12. Maitre S., Jaber K., Perrot J.L., Guy C., Cambazard F. [Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine] (Fr.). Ann Dermatol Venereol 2002, 129:217-219.
13. Lansdown A.B., Williams A. How safe is silver in wound care?. J Wound Care 2004, 13:131-136.
14. Coombs C.J., Wan A.T., Masterton J.P., Conyers R.A., Pedersen J., Chia Y.T. Do burn patients have a silver lining. Burns 1992, 18:179-184.
15. Flohr C., Heague J., Leach I., English J. Topical silver sulfadiazine-induced systemic argyria in a patient with severe generalized dystrophic epidermolysis bullosa. Br J Dermatol 2008, 159:740-741.
16. McKenna S.R., Latenser B.A., Jones L.M., Barrette R.R., Sherman H.F., Varcelotti J.R. Serious silver sulphadiazine and mafenide acetate dermatitis. Burns 1995, 21:310-312.
17. Lockhart S.P., Rushworth A., Azmy A.A., Raine P.A. Topical silver sulphadiazine: side effects and urinary excretion. Burns 1983, 10:9-12.
18. Kulick M.I., Wong R., Okarma T.B., Falces E., Berkowitz R.L. Prospective study of side effects associated with the use of silver sulfadiazine in severely burned patients. Ann Plast Surg 1985, 14:407-419.
19. Eldad A., Neuman A., Weinberg A., Benmeir P., Rotem M., Wexler M.R. Silver sulphadiazine-induced haemolytic anaemia in a glucose-6-phosphate dehydrogenase-deficient burn patient. Burns 1991, 17:430-432.
20. Rastogi S.K., Rutledge V.J., Gibson C., Newcombe D.A., Branen J.R., Branen A.L. Ag colloids and Ag clusters over EDAPTMS-coated silica nanoparticles: synthesis, characterization, and antibacterial activity against Escherichia coli. Nanomed Nanotechnol Biol Med 2011, 7:505-514.
21. Shurygina I.A., Sukhov B.G., Fadeeva T.V., Umanets V.A., Shurygin M.G., Ganenko T.V., et al. Bactericidal action of Ag(0)- antithrombotic sulfated arabinogalactan nanocomposite: coevolution of initial nanocomposite and living microbial cell to a novel non-living nanocomposite. Nanomed Nanotechnol Biol Med 2011 [Epub ahead of print].
22. Nakamura Y., Kano R., Murai T., Watanabe S., Hasegawa A. Susceptibility testing of Malassezia species using the urea broth microdilution method. Antimicrob Agents Chemother 2000, 44:2185-2186.
23. Nakamura Y., Kano R., Watanabe S., Takahashi H., Hasegawa A. Susceptibility testing of Cryptococcus neoformans using the urea broth microdilution method. Mycoses 1998, 41:41-44.
24. Uthman A., Rezaie S., Dockal M., Ban J., Soltz-Szots J., Tschachler E. Fluconazole downregulates metallothionein expression and increases copper cytotoxicity in Microsporum canis. Biochem Biophys Res Commun 2002, 299:688-692.
25. Klasen H.J. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns 2000, 26:131-138.
26. Sano S., Fujimori R., Takashima M., Itokawa Y. Absorption, excretion and tissue distribution of silver sulphadiazine. Burns 1982, 8:278-285.
27. Chaby G., Viseux V., Poulain J.F., De Cagny B., Denoeux J.P., Lok C. [Topical silver sulfadiazine-induced acute renal failure] (Fr). Ann Dermatol Venereol 2005, 132:891-893.
28. Lansdown A.B., Sampson B., Laupattarakasem P., Vuttivirojana A. Silver aids healing in the sterile skin wound: experimental studies in the laboratory rat. Br J Dermatol 1997, 137:728-735.
29. Gregus Z., Klaassen C.D. Disposition of metals in rats: a comparative study of fecal, urinary, and biliary excretion and tissue distribution of eighteen metals. Toxicol Appl Pharmacol 1986, 85:24-38.
30. Klaassen C.D. Biliary excretion of silver in the rat, rabbit, and dog. Toxicol Appl Pharmacol 1979, 50:49-55.
31. Gosheger G., Hardes J., Ahrens H., Streitburger A., Buerger H., Erren M., et al. Silver-coated megaendoprostheses in a rabbit model-an analysis of the infection rate and toxicological side effects. Biomaterials 2004, 25:5547-5556.
32. Carr H.S., Wlodkowski T.J., Rosenkranz H.S. Silver sulfadiazine: in vitro antibacterial activity. Antimicrob Agents Chemother 1973, 4:585-587.
33. Maple P.A., Hamilton-Miller J.M., Brumfitt W. Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1992, 29:661-668.
34. Alio A.B., Mendoza M., Zambrano E.A., Diaz E., Cavallera E. Dermatophytes growth curve and in vitro susceptibility test: a broth micro-titration method. Med Mycol 2005, 43:319-325.
35. Coelho L.M., Aquino-Ferreira R., Maffei C.M., Martinez-Rossi N.M. In vitro antifungal drug susceptibilities of dermatophytes microconidia and arthroconidia. J Antimicrob Chemother 2008, 62:758-761.
36. Yazdanparast S.A., Barton R.C. Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis. J Med Microbiol 2006, 55:1577-1581.
37. Hashimoto T., Blumenthal H.J. Factors affecting germination of Trichophyton mentagrophytes arthrospores. Infect Immun 1977, 18:479-486.
38. Gupta A.K., Ahmad I., Porretta M., Summerbell R.C. Arthroconidial formation in Trichophyton raubitschekii. Mycoses 2003, 46:304-310.
39. Fox C.L., Modak S.M. Mechanism of silver sulfadiazine action on burn wound infections. Antimicrob Agents Chemother 1974, 5:582-588.
40. Bridges K., Lowbury E.J. Drug resistance in relation to use of silver sulphadiazine cream in a burns unit. J Clin Pathol 1977, 30:160-164.
41. Lowbury E.J., Babb J.R., Bridges K., Jackson D.M. Topical chemoprophylaxis with silver sulphadiazine and silver nitrate chlorhexidine creams: emergence of sulphonamide-resistant Gram-negative bacilli. Br Med J 1976, 1:493-496.
42. Hamilton-Miller J.M., Shah S., Smith C. Silver sulphadiazine: a comprehensive in vitro reassessment. Chemotherapy 1993, 39:405-409.
43. Pal S., Tak Y.K., Song J.M. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol 2007, 73:1712-1720.
44. Sondi I., Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci 2004, 275:177-182.
45. Kim J.S., Kuk E., Yu K.N., Kim J.H., Park S.J., Lee H.J., et al. Antimicrobial effects of silver nanoparticles. Nanomed Nanotechnol Biol Med 2007, 3:95-101.
46. Jain J., Arora S., Rajwade J.M., Omray P., Khandelwal S., Paknikar K.M. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use. Mol Pharm 2009, 6:1388-1401.
47. Liu X., Lee P.Y., Ho C.M., Lui V.C., Chen Y., Che C.M., et al. Silver nanoparticles mediate differential responses in keratinocytes and fibroblasts during skin wound healing. ChemMedChem 2010, 5:468-475.
48. Kwan K.H., Liu X., To M.K., Yeung K.W., Ho C.M., Wong K.K. Modulation of collagen alignment by silver nanoparticles results in better mechanical properties in wound healing. Nanomed Nanotechnol Biol Med 2011, 7:497-504.
49. Arima Y., Nakai Y., Hayakawa R., Nishino T. Antibacterial effect of beta-thujaplicin on staphylococci isolated from atopic dermatitis: relationship between changes in the number of viable bacterial cells and clinical improvement in an eczematous lesion of atopic dermatitis. J Antimicob Chemother 2003, 51:113-122.
50. Travers J.B., Kozman A., Mousdicas N., Saha C., Landis M., Al-Hassani M., et al. Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid. J Allergy Clin Immunol. 2010;125:146-52, e1-2.
51. Baker B.S. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006, 144:1-9.
52. Casagrande B.F., Fluckiger S., Linder M.T., Johansson C., Scheynius A., Crameri R., et al. Sensitization to the yeast Malassezia sympodialis is specific for extrinsic and intrinsic atopic eczema. J Invest Dermatol 2006, 126:2414-2421.
53. Biedermann T. Dissecting the role of infections in atopic dermatitis. Acta Derm Venereol 2006, 86:99-109.
54. Yoshino T., Asada H., Sano S., Nakamura T., Itami S., Tamura M., et al. Impaired responses of peripheral blood mononuclear cells to staphylococcal superantigen in patients with severe atopic dermatitis: a role of T cell apoptosis. J Invest Dermatol 2000, 114:281-288.